MedTrace Logo

Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel

NCT06043921 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-09-21

No results posted yet for this study

Summary

This is a multicenter, prospective, observational study to evaluate the utility of the Invitae Personalized Cancer MonitoringTM assay for patients with resectable and unresectable pancreatic cancer. Using tumor tissue, a personalized blood test (the Invitae Personalized Cancer MonitoringTM test) will be developed that can be used for repeated monitoring to assess for the presence or absence of circulating tumor DNA (ctDNA). The presence of residual cancer cells after treatment is known as molecular residual disease (MRD) and the detection of ctDNA can provide evidence of the presence of MRD. Participants in this study will have their blood drawn at various time points throughout their cancer treatment to test for ctDNA and monitoring with the Invitae Personalized Cancer MonitoringTM test will continue until disease progression or the duration of the study.

Conditions

Interventions

OTHER

No intervention

There is no intervention associated with this observational study.

Sponsors & Collaborators

  • National Cancer Center Hospital East

    collaborator OTHER

  • Invitae Corporation

    lead INDUSTRY

Principal Investigators

  • Taro Shibuki, MD · Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Japan

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06043921 on ClinicalTrials.gov